Stock OLMA OLEMA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Olema Pharmaceuticals, Inc.

Equities

OLMA

US68062P1066

Market Closed - Nasdaq
Other stock markets
 01:30:00 08/05/2024 am IST 		5-day change 1st Jan Change
11.24 USD +3.12% Intraday chart for Olema Pharmaceuticals, Inc. +10.52% -19.89%
02/04 Goldman Sachs Initiates Olema Pharmaceuticals at Buy With $24 Price Target MT
18/03 Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to S&P Biotechnology Select Industry Index CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Olema Oncology Announces New Clinical Data for Palazestrant in Combination with Ribociclib to be Presented at the 2024 ESMO Breast Cancer Annual Congress
GL
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Olema Oncology to Participate in Upcoming Investor Conferences in May
GL
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
GL
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Goldman Sachs Initiates Olema Pharmaceuticals at Buy With $24 Price Target
MT
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to S&P Biotechnology Select Industry Index
CI
HC Wainwright Adjusts Price Target on Olema Pharmaceuticals to $25 From $28, Maintains Buy Rating
MT
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
GL
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
GL
Olema Oncology Announces Publication of Data Highlighting Palazestrant’s Ability to Inhibit Wild-Type and Mutant ER+ Breast Cancer Both as Monotherapy and in Combination with CDK4/6 Inhibitors
AQ
Olema Oncology Announces Publication of Data Highlighting Palazestrant?s Ability to Inhibit Wild-Type and Mutant Er+ Breast Cancer Both as Monotherapy and in Combination with Cdk4/6 Inhibitors
CI
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Olema Oncology to Participate in Upcoming Investor Conferences
GL
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
Citigroup Initiates Olema Pharmaceuticals at Buy With $20 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OLMA Stock
  4. News Olema Pharmaceuticals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW